What changed in this filing

/stocks — the workspaceLOADING

Item 2. Unregistered Sales of Equity Securities

2021-03-17 compared with 2020-12-18 · 15 added, 65 removed, 3 unchanged (96% of the section changed)

Unregistered Sales of Equity Securities and Use of Proceeds

We issued the following securities during

the nine months ended July 31, 2020 to the date of filing of this Report:

On October 10, 2019, the Company and an investor (“Noteholder”) agreed to a funding

facility arrangement (“Funding Facility”) whereby the Noteholder was required to fund the Company an initial tranche

of $100,000 on October 15, 2019 (“Initial Funding Date”) and had the option to fund the Company up to an aggregate

of $500,000 (“Funding Facility Limit”) in minimum $100,000 monthly tranches by no later than February 15, 2020 (“Funding

Expiration Date”).

The Funding Facility matures on February 15, 2021 (“Maturity Date”) and accrues interest at

6.0% per annum.

The Funding Facility, plus all accrued interest, automatically converts into 40,000,000 shares of newly issued

common stock of the Company if the Noteholder funds the full $500,000 by the Funding Expiration Date.

The Noteholder fully funded

the Funding Facility as prescribed on February 12, 2020 and the Company converted the Funding Facility into 40,000,000 shares of

common stock of the Company that were issued to the Noteholders designated entity, Republic Asset Holdings LLC.

On April 27, 2020, the Company

sold 5,000,000 shares of common stock to Republic Asset Holdings LLC., a Company controlled by Michael Carbonara, a director of

the Company, at $0.02 per share for an aggregate purchase price of $100,000.

The proceeds were used for working capital.

During November 2019 through January 2020, the Company sold 3,250,000 shares of common stock to

three “accredited investors”

at $0.02 per share for an aggregate purchase price of $65,000.

The proceeds were used

for working capital.

During February 2020 through April 2020, the Company sold 11,050,000 shares of common stock to

five “accredited investors”

at $0.02 per share for an aggregate purchase price of $221,000.

The proceeds were used

for working capital.

During April 2020 through May 2020, the Company sold 11,000,000 shares of common stock to Dr.

Meglin, a director of the Company at $0.02 per share for an aggregate purchase price of $220,000.

During July, August and October

2020, the Company sold an additional 1,166,666 shares, 422,514 shares, and 625,000 shares of common stock to Dr.

Allen Meglin at

$0.03 per share, $0.10 per share and $0.08 per share, respectively, for an aggregate purchase price of $127,251.

The proceeds from

all of the above sales were used for working capital.

During May 2020, the Company sold 3,000,000 shares of common stock to two “accredited investors”

at $0.02 per share for an aggregate purchase price of $60,000.

The proceeds were used for working capital.

During July and August 2020, the Company completed the private placement to 19 accredited investors

for the sale of 13,499,992 shares of Common stock of the Company at a selling price of $0.03 per share for an aggregate amount

of $405,000 (“Sale”).

The proceeds are being used to fund the Company’s public company financial reporting requirements.

During July 2020, the Company sold 1,000,000 shares of common stock to two “accredited investors”,

at $0.02 per share and $0.03 per share, respectively for an aggregate purchase price of $25,000.

The proceeds were used for working

During August 2020, the Company sold 8,606,665 shares of common stock to nine “accredited

investors”, at prices ranging from $0.03 per share and $0.06 per share, for an aggregate purchase price of $392,100.

proceeds were used for working capital.

During September 2020, the Company sold 4,800,000 shares of common stock to five “accredited

investors”, at prices ranging from $0.06 per share and $0.10 per share, for an aggregate purchase price of $410,000.

Sales of Equity Securities and Use of Proceeds

issued the following securities during the three months ended January 31, 2021 and through the date of this Quarterly Report on

November 2020, the Company sold 800,000 shares of common stock to an “accredited

investor”, at $0.05 per share, for an aggregate purchase price of $40,000.

proceeds were used for working capital.

During October 2020, the Company sold 2,033,333 shares of common stock to five “accredited

investors”, at prices ranging from $0.06 per share and $0.10 per share, for an aggregate purchase price of $170,000.

February 2021, the Company sold an aggregate of 12,340,910 shares of common stock to

five “accredited investors”, at prices ranging from $0.05 per share to $0.06

per share for an aggregate purchase price of $665,000.

The proceeds were used for working

February 22, 2021, the Company sold 1,818,181 shares of common stock to Republic Asset

Holdings LLC., a limited liability company controlled by Michael Carbonara, a director

of the Company, at $0.055 per share for an aggregate purchase price of $100,000.

proceeds were used for working capital.

During October 2020, the Company and the holder of the $20,000 debenture agreed to convert the

principal amount of the $20,000 debenture plus interest accrued and unpaid through the date of the conversion totaling approximately

$20,300 into 160,000 shares of common stock of the Company.

During November 2020, the Company sold 800,000 shares of common stock to an “accredited investor”,

at $0.05 per share, for an aggregate purchase price of $40,000.

The proceeds were used for working capital.

None of the above issuances involved any

underwriters, underwriting discounts or commissions, or any public offering and we believe were exempt from the registration requirements

of the Securities Act of 1933, as amended (the “Securities Act”) by virtue of Section 4(a)(2) and Regulation D promulgated

of the above issuances involved any underwriters, underwriting discounts or commissions, or any public offering and we believe

were exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) and Regulation D promulgated

thereunder due to the fact that there was no solicitation or advertising and the did not involve a public offering of securities.

Defaults upon Senior Securities

Mine Safety Disclosures

upon Senior Securities

Safety Disclosures

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Unregistered Sales of Equity Securities